Viz ICH

by Viz.ai  · Based in United States → — AI-Powered Disease Detection and Intelligent Care Coordination
Emergency Medicine Neurosurgery Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Viz.ai is a leader in AI-powered care coordination and clinical workflow solutions, deployed in nearly 2,000 hospitals across the United States and Europe. Its flagship platform, Viz.ai One, uniquely combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz ICH is a specific AI-powered software within the Viz.ai One Neuro Suite designed for the detection and triage of intracranial hemorrhage (ICH). It utilizes advanced AI algorithms to detect and localize various forms of ICH, including epidural, subdural, subarachnoid, and intraparenchymal hemorrhage, in real time. The tool also provides automated and consistent quantification of hemorrhage volume, lateral ventricle dimensions, and midline shift, which is crucial for assessing severity, monitoring progression, and planning treatment strategies.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated detection of suspected intracranial hemorrhage (ICH) including subdural hematoma (SDH)
  • Real-time ICH detection and quantification of hemorrhage volume, lateral ventricle dimensions, and midline shift
  • AI-powered alerts and notifications to care teams
  • HIPAA-compliant communication platform for multidisciplinary teams
  • High-fidelity imaging access on mobile and web devices
  • Integration with radiology workflow (PACS)
  • Streamlined clinical workflow and care coordination
  • Supports ICH scoring and documentation in alignment with AHA requirements
  • Reduces inter-hospital transfer times
  • Clinically validated AI solution with real-world evidence

Use Cases

  • Accelerating diagnosis and triage of intracranial hemorrhage patients
  • Optimizing care coordination for neurovascular emergencies
  • Reducing time to treatment for ICH and other stroke-related conditions
  • Improving efficiency in clinical workflows and decision-making
  • Facilitating faster and more efficient patient transfers
  • Enhancing documentation and compliance with clinical guidelines

What Physicians Need to Know

Stroke Detection Speed
Viz.ai's platform significantly reduces time to diagnosis and notification for stroke. The median time to alert for Large Vessel Occlusion (LVO) is typically 10-11 minutes. AI analyzes CT scans in 1-6 minutes, cutting door-to-notification time by 30-52% compared to traditional workflows. For Intracerebral Hemorrhage (ICH), Viz ICH Plus delivers automated volume calculation results nearly three times faster than manual methods.
Brain MRI/CT Analysis
Viz ICH and Viz ICH+ automatically detect suspected acute intracerebral hemorrhage (ICH) and quantify hyperdensities, midline shift, and lateral ventricles on non-contrast CT images. Viz SDH identifies suspected acute and chronic subdural hematomas. The platform also includes Viz LVO for analyzing CTA images for large vessel occlusions and Viz CTP for automated analysis of CT perfusion images to assess ischemic penumbral and Tmax within minutes. It provides AI-enhanced 3D imaging for clear neurovasculature visualization.
Large Vessel Occlusion Detection
Viz LVO auto-detects suspected large vessel occlusions (LVOs) within seconds of image acquisition. It demonstrates high sensitivity (90.6-96.3%) and specificity (87.5-93.8%) for LVO detection, with a median time to alert of 10-11 minutes. The algorithm identifies anterior circulation LVOs from ICA-T to M1/M2 segments and has been shown to reduce critical stroke care metrics like door-to-transfer and door-to-puncture times.
Triage Prioritization Speed
Viz.ai's platform is designed for rapid triage, analyzing CT scans in 1-6 minutes and reducing door-to-notification time by 30-52%. The median door-to-neurointerventionalist notification time was reduced by 39.5 minutes with AI. For LVOs, 90% of alerts are reviewed by the intended specialist within 5 minutes. Viz ICH provides real-time detection and quantification, supporting faster assessment and documentation, and the platform prioritizes worklists for acute findings.
ASPECTS Score Automation
Viz.ai integrates Avicenna.AI's CINA-ASPECTS tool, which automatically assesses the Alberta Stroke Program Early CT Score (ASPECTS) from CT brain images, providing an objective and reliable measure of stroke severity.
Mobile Notification System
The system features a real-time, HIPAA-compliant mobile application for dynamic viewing of high-fidelity images on Apple and Android devices. It enables group communication messaging and secure mobile communication among care teams. Notifications are customizable, allowing users to set preferences for push notifications or text messages, choose notification sounds, and override silent/do not disturb modes. Secure login options include password, fingerprint, or FaceID.
Physician Tip

Leverage Viz.ai's rapid AI detection and quantification for ICH and LVO to significantly reduce diagnosis and notification times, enabling quicker treatment decisions. Utilize the mobile platform for real-time image review, secure communication, and efficient care team activation, especially for time-sensitive conditions like stroke. Employ automated measurements (e.g., ICH volume, midline shift, ASPECTS score) for consistent, objective assessment and streamlined documentation, reducing manual variability. Customize notification settings to ensure critical alerts are received promptly without unnecessary interruptions, optimizing personal workflow and improving patient outcomes.

Viz.ai One is designed for extensive interoperability, integrating seamlessly with existing PACS (Picture Archiving and Communication Systems) and EHR (Electronic Health Record) systems. It also expands to integrate with radiology worklist systems. Viz.ai collaborates with Microsoft Cloud for Healthcare for secure, scalable AI deployment and partners with Salesforce to extend real-time clinical intelligence and trigger workflows. The platform supports integration with third-party AI tools, such as Avicenna.AI for ASPECTS scoring and Cercare Medical for perfusion analysis. Additionally, it can integrate with communication platforms like Pulsara to enhance workflows and facilitate collaboration.

Details

Category Neurology AI, Radiology & Imaging AI, Triage & ER/ICU AI
Pricing Contact for pricing — Enterprise solution; subscription-based
DeploymentCloud-native; integrates with existing IT frameworks (EHR, PACS)
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Yes AI-estimated

The FDA granted 510(k) clearance for Viz ICH Plus software (K210209), which utilizes artificial intelligence to help quantify intracerebral hemorrhage on non-contrast computed tomography (CT) images. It offers automated detection, labeling, and volume quantification for segmentable brain structures.
Integrations
EHR Not specified
Specialties Emergency Medicine, Neurosurgery, Radiology

What the Web Says

Viz ICH is an AI-powered platform designed to enhance the detection, diagnosis, and management of intracerebral hemorrhage (ICH) by analyzing non-contrast brain CT scans. It aims to reduce time to treatment and improve patient outcomes through automated detection, volume measurement, and real-time alerts to care teams. The platform is primarily adopted by hospitals and health systems, integrating with existing radiology workflows.

Overall: Positive

Strengths

  • High diagnostic accuracy for ICH detection, particularly for larger hemorrhages, with reported sensitivities between 84.7% and 89.3% and specificities between 98.1% and 99.4%.
  • Significantly reduces interhospital transfer times for ICH patients, with one case study showing a reduction from an average of 200 minutes to 101 minutes.
  • Automates accurate volume measurements of brain bleeds, which is crucial for assessing severity and guiding treatment decisions, and is nearly three times faster than manual methods.
  • Expedites care team coordination through real-time alerts to physicians (radiologists, neurologists, neurosurgeons, ER physicians) via mobile applications, even before formal reads are completed.
  • Enhances radiologists' workflow by accurately detecting negative ICH cases, reducing unnecessary reviews, and focusing interpretation on specific regions.
  • Improves efficiency in clinical workflows and supports faster, more effective care decisions.

Limitations

  • Sensitivity for certain ICH subtypes, such as intraventricular hemorrhage, can be lower (e.g., 44%).
  • Occasionally flags subsegmental pulmonary embolisms that may not be clinically significant, though sensitivity is considered a worthwhile trade-off by some.
  • Enterprise-only pricing makes it inaccessible to individual physicians.
  • May poorly differentiate between atrial intraventricular hemorrhage (IVH) and ICH in large, multiloculated bleeds, requiring manual double-checking.
  • Some false positives, though many are for other significant findings that still benefit from expedited review.

Based on reviews from: PMC, Clinical AI Report, Neurology, NeuroNews, American Heart Association Journals, ResearchGate, Viz.ai, MDPI, Reddit, Business Wire, PubMed

Last updated: 2026-07-21

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Viz ICH

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

NeuroNews
Viz.ai announces case study demonstrating reduced ICH transfer time with AI-powered care coordination
Viz.ai announced new clinical data highlighting how Viz ICH and Viz ICH Plus optimize care for intracerebral hemorrhage (ICH) patients by significantly reducing interhospital transfer time through AI-powered detection and quantification. A case study showed a reduction in transfer time from an average of 200 minutes to 101 minutes, leading to successful surgical evacuation and neurological recovery.
2025-06
Business Wire
New Study Demonstrates AI-Powered Care Coordination Reduces Transfer Time and Improves Outcomes in Intracerebral Hemorrhage Patients
Viz.ai released new clinical data demonstrating the positive impact of Viz ICH and Viz ICH Plus on intracerebral hemorrhage (ICH) patient care, showing that AI-powered detection and quantification significantly reduced interhospital transfer time. This expedited treatment and improved patient outcomes, as evidenced by a case where transfer time was nearly halved.
2025-06
PMC (Cureus)
Optimizing Intracerebral Hemorrhage Management and Interhospital Transfer With Viz ICH Plus AI Technology
This case study details the integration of Viz ICH Plus into a Neuroemergencies Management and Transfer (NEMAT) program, showcasing a significant reduction in interhospital transfer time for an ICH patient. The AI-powered system promptly identified a hematoma, cutting transfer time from approximately 200 to 101 minutes and improving patient outcomes.
2025-03
Viz.ai
Two New Clinical Studies Demonstrate Accuracy of Viz.ai Algorithm for Intracranial Hemorrhage Volume Measurements to Advance Timely, Critical Treatment Decisions
Viz.ai announced new clinical data from two independent studies validating the accuracy and clinical utility of its AI-powered hyperdensity measurement solution, Viz ICH Plus, for intracranial hemorrhage management. The studies highlighted its ability to accurately and efficiently measure hemorrhage volume, quantify lateral ventricular volume, and estimate midline shift.
2025-04
PMC (Cureus)
Revolutionizing Intracranial Hemorrhage Diagnosis: A Retrospective Analytical Study of Viz.ai ICH for Enhanced Diagnostic Accuracy
A retrospective analytical study indicated that Viz.ai ICH demonstrates promising performance in detecting intracerebral hemorrhage (ICH) with 85% sensitivity and 98% specificity. The AI model accurately detects ICH on non-contrast brain CT, particularly for larger volume hemorrhages, enhancing radiologists' workflow.
2024-08
RC Capital
Viz.ai and NICO Corporation Announce Collaboration to Improve Outcomes in Patients with Intracerebral Hemorrhage
Viz.ai partnered with NICO Corporation to enhance outcomes for intracerebral hemorrhage patients by combining Viz.ai's AI-powered disease detection and care coordination with NICO's minimally-invasive neurosurgical technologies. This collaboration aims to leverage AI modules like Viz ICH and Viz ICH Plus to assist neurosurgeons and improve patient care.
2024-04
Practical Neurology
Viz.ai's Intracerebral Hemorrhage Algorithm Gains FDA Clearance
Viz.ai received FDA 510(k) clearance for its Viz ICH Plus algorithm, designed for intracranial hemorrhage (ICH) detection and care coordination. This software automates the identification, labeling, and quantification of brain structures on non-contrast CT scans, aiming to transform the approach to ICH cases.
2024-02
Diagnostic Imaging
FDA Clears AI Software for Assessing Intracerebral Hemorrhage on Non-Contrast CT
The FDA granted 510(k) clearance to Viz ICH Plus software, an AI-powered tool that quantifies intracerebral hemorrhage on non-contrast CT images. This software provides automated detection, labeling, and volume quantification for brain bleeds, which is crucial for timely diagnosis and treatment decisions in ICH cases.
2024-02

Videos

Product demos, reviews, and walkthroughs for Viz ICH.

View all on YouTube

Frequently Asked Questions

Viz ICH Plus seamlessly integrates into workflows for radiologists, neurologists, and neurosurgeons by automating the identification, labeling, and quantification of ICH on non-contrast CT images. It provides real-time alerts and measurements on desktop and mobile devices, facilitating faster triage and treatment decisions.
Yes, Viz ICH Plus received FDA 510(k) clearance in February 2024 for automating ICH quantification. Viz.ai maintains a comprehensive HIPAA compliance program, including administrative, technical, and physical safeguards for Protected Health Information (PHI), and undergoes regular SOC 2 Type II + HIPAA audits.
Other AI platforms in stroke management include RapidAI and Aidoc. While Viz.ai focuses on comprehensive care coordination, RapidAI is also a prominent player with validated imaging software, and Aidoc offers computer-aided triage solutions for ICH detection.
Specific pricing for Viz ICH is not publicly disclosed, as it's typically part of an enterprise platform (Viz.ai Oneu2122) for hospitals and health systems. Viz.ai offers tools to assess potential economic impact, estimating additional treatment revenue, imaging, and follow-up consultations.
While Viz ICH demonstrates high accuracy, particularly for larger ICH volumes, studies note its sensitivity can vary by ICH subtype (e.g., lower for intraventricular hemorrhage). Like all AI tools, it should augment, not replace, clinical judgment, and its performance can be influenced by image quality and specific clinical scenarios.
Viz ICH Plus has demonstrated high accuracy in quantifying ICH volume, bilateral lateral ventricle volume, and midline shift, achieving up to 92.3% accuracy in identifying clinically meaningful findings. In a retrospective study, Viz.ai ICH showed an overall sensitivity of 85% and specificity of 98% for ICH detection, with sensitivity increasing to 94% for intraparenchymal hemorrhages.
Viz ICH automates the detection and quantification of ICH, providing real-time alerts to care teams, which can significantly reduce interhospital transfer times and expedite treatment. This streamlined workflow supports faster decision-making and more efficient patient management.

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Paid
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

More from Viz.ai

ContaCT
Viz.AI
Neurology AI
Viz.ai is a pioneering AI-powered care coordination platform that accelerates disease detection and streamlines clinical workflows. With multiple FDA clearances, including the initial Viz.AI Contact application for stroke, it helps ensure patients receive timely treatment across over 1,700 hospitals globally.
Subscription-based
Viz AAA
Viz.ai
Cardiology AI
Viz AAA is the first FDA-cleared AI-powered solution by Viz.ai for the detection and triage of suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans, designed to accelerate diagnosis and care coordination.
Subscription model
Viz ANEURYSM
Viz.ai
Neurology AI
Viz ANEURYSM is an FDA-cleared AI-powered solution by Viz.ai that auto-detects suspected cerebral aneurysms in CT angiograms (CTAs), streamlining neurovascular care coordination and facilitating timely patient management.
Contact for pricing
Viz CTP
Viz.ai
Clinical Decision Support & Reference
Viz.ai is a pioneer in AI-powered disease detection and intelligent care coordination, leveraging over 50 FDA-cleared algorithms to analyze medical imaging and streamline clinical workflows for faster diagnosis and treatment.
Subscription model

View company profile →

Suggest an Edit → | Last Verified: 2026-04-21 | First Added: 2026-04-21

Investors who backed Viz ICH

Funded through the company that built this tool.

Scale Venture Partners
VC T3
Foster City, United States
$5M-$25M
Scale Venture Partners is a Foster City-based growth-stage software firm investing primarily in B2B SaaS, with a long track record of leading…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
AI Tool Finder
AI-powered search. Results may not be comprehensive.